Future Oncology · 2019 · 16 citations · 15 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyGastrointestinal OncologyCancer Survival AnalysisChemotherapy Toxicity ManagementToxicity ManagementAnticancer ChemotherapyChemotherapy Response AssessmentChemotherapy-induced Gastrointestinal ToxicityClinical Trial Efficacy EndpointsCox RegressionGastric Cancer PharmacotherapyLiposomesOxaliplatin-based Therapy
Aim: To compare the performance of first-line paclitaxel liposome + oxaliplatin and SOX (tegafur/gimeracil/oteracil + oxaliplatin) in advanced gastric cancer patients. Materials & methods: Stage IIb–IV gastric cancer patients underwent either first-line paclitaxel liposome + oxaliplatin (n = 52) or SOX (n = 69) between 2010–2013, and followed up until 2015 or death. Results: Both groups had similar objective response rate (p = 0.48) and disease control rate (p = 0.992) after two chemotherapy cycles, median progression-free survival (p = 0.495) and median overall survival (p = 0.208). Liposome group had significantly lower rate of grade I–II platelet decline and liver function damage (p = 0.04 and 0.019). Multivariate COX regression identified pre-treatment neutrophil-to-lymphocyte ratio as an independent prognostic factor. Conclusion: First-line paclitaxel liposome + oxaliplatin has comparable efficacy, but causes reduced adverse reactions in advanced gastric cancer as compared with SOX.
15
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Jacques Ferlay, Hai‐Rim Shin, Freddie Bray et al. · International Journal of Cancer · 2010 · 21.4K citations